NCT05716113View on ClinicalTrials.gov

CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
NeoplasmsHematologic NeoplasmsNeoplasms by SiteHematologic Diseases
Interventions
DRUG

RD13-02 cell infusion

CAR-T cells

Trial Locations (1)

310003

The first affiliated hospital of medical college of zhejiang university, Hangzhou

All Listed Sponsors
collaborator

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY

lead

He Huang

OTHER